2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1787

Efficacy and Safety of Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Patients with Non-Radiographic Axial Spondyloarthritis
Abstract Number: 2474

Efficacy and Safety of Extending Tocilizumab Infusion Intervals from 4 Weeks to 6 Weeks in Patients with Rheumatoid Arthritis
Abstract Number: 1L

Efficacy and Safety of Intra-Articular Sprifermin in Symptomatic Radiographic Knee Osteoarthritis: Results of the 2-Year Primary Analysis from a 5-Year Randomised, Placebo-Controlled, Phase II Study
Abstract Number: 2969

Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to TNF Inhibitors: 52-Week Results from a Phase 3 Study
Abstract Number: 930

Efficacy and Safety of Modified-Release Prednisone in Managing Moderate Activity SLE during Pregnancy: An Implemented Case-Control Study
Abstract Number: 1974

Efficacy and Safety of Pregabalin for Fibromyalgia in a Population of Chinese Patients: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
Abstract Number: 2445

Efficacy and Safety of Rituximab Biosimilar, CT-P10, after a Single Switch from Innovator Rituximabs in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 72 Weeks
Abstract Number: 2167

Efficacy and Safety of Rituximab in Anti-Synthetase Positive and Negative Patients with Idiopathic Inflammatory Myopathy– a Registry-Based Study
Abstract Number: 1195

Efficacy and Safety of Subcutaneous Tanezumab in Patients with Knee or Hip Osteoarthritis (NCT01089725)
Abstract Number: 2482

Efficacy and Safety of Switching from Adalimumab to Sarilumab in an Open-Label Extension of a Phase 3 Monotherapy Trial in Patients with Active Rheumatoid Arthritis
Abstract Number: 2493

Efficacy and Safety of Tofacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Prior Therapies
Abstract Number: 6L

Efficacy and Safety of Ustekinumab, an Interleukin 12/23 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: Results of a Phase 2, Randomized Placebo-Controlled Study
Abstract Number: 2L

Efficacy and Safety Results from a Phase 2 Trial of Risankizumab, a Selective IL-23p19 Inhibitor, in Patients with Active Psoriatic Arthritis
Abstract Number: 2878

Efficacy and Safety Results of Guselkumab in Patients with Active Psoriatic Arthritis over 56 Weeks from a Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study
Abstract Number: 2489

Efficacy and Survival of Biologic DMARD Therapies As Monotherapy: Real World Data

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].